International Journal of Applied Pharmaceutics

ISSN- 0975-7058 Vol 15, Issue 1, 2023

Original Article

IDENTIFICATION OF POTENTIAL ACTIVITY OF VOLATILE COMPOUNDS DERIVED FROM *POGOSTEMON CABLIN* BENTH AS ANTIVIRAL OF SARS-COV-2

YULANDA ANTONIUS, JEREMI ONGKO, POPY HARTATIE HARDJO*

Department of Biology, Faculty of Biotechnology, University of Surabaya, Indonesia
***Email: poppy_hardjo@staff.ubaya.ac.id**

Received: 11 Nov 2021, Revised and Accepted: 11 Nov 2022

ABSTRACT

Objective: Coronavirus disease-19 (COVID-19) is global pandemic which caused by SARS-CoV-2 infection. Mechanism of infection is initiated by attachment between viral glycoprotein with ACE2 receptor in human cells. Furthermore, Indonesia had a massive diversity of plants with a high potency of drugs, such as *Pogostemon cablin* Benth. In brief, it contained of various volatile compounds with many therapeutic properties. Therefore, this research aimed to identify the ability of volatile compounds from *Pogostemon cablin* Benth as a potential inhibitor of SARS-CoV-2 spike glycoprotein.

Methods: SMILE notation of 22 volatile compounds of *Pogostemon cablin* Benth were collected from PubChem and the 3D structure of SARS-CoV-2 glycoprotein (PDB ID: 6VXX) was obtained from PDB database. Simulation of interaction between volatile compound and glycoprotein was conducted by using Pyrx molecular docking. Moreover, the complex of compounds-glycoprotein was depicted by using Chimera and the amino acid residue was analysed by using LigPlot. Selected potential compounds were identified for biological activity prediction, drug-likeness, and toxicity analysis.

Results: Analysis showed that among those volatile compounds, only caryophyllene oxide (-6.3 kcal/mol) naturally bind specific into RBD site as compared to the control. Furthermore, it had comparable hydrogen and hydrophobic interactions with glycoprotein. Further analysis showed it has strong potential biological function for antiviral with low toxicity.

Conclusion: Caryophyllene oxide is considered as promising candidate compounds that inhibited viral infection through SARS-CoV-2 glycoprotein.

Keywords: Inhibitor compound, Glycoprotein, Secondary metabolite, Viral infection

© 2023 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/)
DOI: https://dx.doi.org/10.22159/ijap.2023v15i1.43571. Journal homepage: https://innovareacademics.in/journals/index.php/ijap

INTRODUCTION

As mega diversity country, Indonesia is known as a tropical country with high flora and fauna variety. Various flora in Indonesia is considered for having a huge potency to be developed as a therapeutic agent [1]. There are about 7,500 medicinal plants which varied from wild plant, to cultivated, or introduced species in Indonesia [2, 3]. *Pogostemon cablin* Benth is known as aromatic plant with various therapeutic function. The volatile compound of its plant is widely used as aromatherapy for treatment, especially for patchouli oil. Among various variety of *Pogostemon cablin* Benth, the Sidikalang variant is considered as the most outstanding variant in Indonesia, which had international trade quality for production. It is commonly used for patchouli oil supply for various potential function in industry or the medicinal field [4]. However, another various volatile compounds of *P. cablin* Benth is also needed to be explored of its function.

The viral infection of SARS-CoV-2 was recently spread across the globe as a pandemic in 2019 up to the present. In brief, SARS-CoV-2 is enveloped virus with single-strand RNA that had several part, such as nucleocapsid protein, membrane, envelope, and glycoprotein [5]. Glycoprotein of SARS-CoV-2 is a transmembrane protein which located in the surface of virion with an essential function for infection. It mediated the attachment of interaction between SARS-CoV-2 with human cells. As structural, SARS-CoV-2 glycoprotein consisted of a receptor binding domain (RBD) with a specific receptor binding motif (RBM) as a site for infection [6]. Several treatments by using any FDA-approved drugs were utilized, such as chloroquine, hydroxychloroquine, and others [7]. Moreover, various strategy development, including chemical and compounds agent, were explored to identify the most potential antiviral which can be utilized as a drug for treatment. Therefore, this study aimed to identify the potency of volatile compounds derived from *Pogostemon cablin* Benth as a potential inhibitor to bind into RBD in SARS-CoV-2 for an inhibitory-based therapeutic agent.

MATERIALS AND METHODS

Sample preparation

Twenty two data of volatile compounds derived from *Pogostemon cablin* Benth were collected from PubChem database (https://pubchem.ncbi.nlm.nih.gov/). The data of ID number and canonical simplified molecular-input line-entry system (SMILES) of each compounds were collected for analysis. Moreover, the 3D structure of each compound was collected in sdf. Format.

Moreover, the 3D structure of SARS-CoV-2 glycoprotein was obtained from Protein Data Bank (PDB) database (https://www.rcsb.org/) with PDB ID 6VXX. The non-essential molecules, such as water molecule and native ligand as NAG were removed by using Chimera. Furthermore, protein structure was added by hydrogen polar as preparation for further analysis. The MLN-4760 and sulabiroins A were selected as control for the analysis [8].

Simulation of molecular docking and visualization of complex compounds-glycoprotein SARS-CoV-2

The simulation of the interaction between 22 volatile compounds and glycoprotein of SARS-CoV-2 was conducted by using molecular docking analysis. The simulation process was performed by using Autodock Vina in Pyrx software. The molecular docking process was done by using blind docking in order to identify the natural ability of each compound to interact with the receptor-binding domain (RBD) of the glycoprotein of SARS-CoV-2. Furthermore, the results of the binding affinity score were compared to the control and other compounds to obtain a candidate of a potent inhibitor. The complexes of the glycoprotein of SARS-CoV-2 and potent compounds were visualized by using Chimera software. Moreover, the amino acid residue was analyzed by using LigPlot software.

Biological activity prediction of potential compounds derived from *Pogostemon cablin* Benth

The biological activity of potent compounds was identified by using PASS Online webserver (http://way2drug.com/passonline/). Several biological activities were selected for identification, such as antiviral, anti-inflammatory, and apoptosis agonists. Score of each probability of activity (Pa) and probability of inactivity (Pi) were collected. Each of score was varied from 0-1.0. In brief, score of $Pa<0.7$ suggested high potential, $0.5<Pa<0.7$ exhibited moderate potential, and $Pa<0.5$ showed poor potential [9-11].

Druglikeness analysis of potential compounds derived from *Pogostemon cablin* Benth

The druglikeness of potent compounds was identified by using SWISS ADME webserver (http://www.swissadme.ch/index.php). Several parameters were selected for analysis based on the Lipinski's rule of five, such as molecular weight (MW)<500 g/mol, H-bond donor<5, H-bond acceptor<10, calculated LogP (ClogP)<5, and molecular refractivity 40-130. Compound which fulfil each of parameter was considered with acceptable potency as a potential drug.

Toxicity prediction of potential compounds derived from *Pogostemon cablin* Benth

Selected potential compounds were addressed for analysis of toxicity prediction by using ProTox-II (https://tox-new.charite.de/protox_II/). The analysis was conducted by submitting the canonical SMILE of selected compounds [12]. Result of analysis was determined by six class of toxicity and predicted LD50.

RESULTS AND DISCUSSION

This study is focused to identify the potency of various volatile compounds of *Pogostemon cablin* Benth targeted the SARS-CoV-2 glycoprotein. SARS-CoV-2 is known as an essential protein which mediated the viral infection and pathogenesis. In brief, the glycoprotein is composed of 1260 amino acids with S1 subunit that contain of receptor-binding domain (RBD). This is an essential region which had ability to contact with ACE2 receptor in human cells. Recent research showed that 17 residues of RBD are in contact with 20 residues of ACE2 receptor. This interaction is suggested as virus-receptor engagement process [13].

Twenty two volatile compounds of *Pogostemon cablin* Benth were selected as a samples for analysis (table 1). Furthermore, MLN-4760 was selected as control and sulabiroins A was selected as reference control. Recent research demonstrated that sulabiroins A which derived from propolis had the most potential ability to inhibit SARS-CoV-2 protein related to the viral infection [8]. Therefore, the sulabiroins A is considered as a reference for comparation.

Table 1: Various volatile compounds derived from *Pogostemon cablin* benth

No	Compounds	PubChem ID	Canonical SMILES
1	Patchouli alcohol	10955174	CC1CCC2(C(C3CCC2(C1C3)C)(C)C)O
2	α-Patchoulene	521710	CC1CCC23C1CC(C2(C)C)CC=C3C
3	Beta-patchoulene	101731	CC1CCC2=C1CC3CCC2(C3(C)C)C
4	α-Guaiene	5317844	CC1CCC(CC2=C1CCC2C)C(=C)C
5	β-Guaiene	15560252	CC1CCC(=C(C)C)CC2=C1CCC2C
6	β-Caryophyllene	5281515	CC1=CCCC(=C)C2CC(C2CC1)(C)C
7	Trans-Caryophyllene	5354499	CC1=CCCC(=C)C2CC(C2CC1)(C)C
8	(E)-β-Caryophyllene [(+)-beta-Caryophyllene]	20831623	CC1=CCCC(=C)C2CC(C2CC1)(C)C
9	β-Elemene	6918391	CC(=C)C1CCC(C(C1)C(=C)C)(C)C=C
10	gamma-elemene	6432312	CC(=C1CCC(C(C1)C(=C)C)(C)C=C)C
11	Pogostone	54695756	CC1=CC(=C(C(=O)O1)C(=O)CCC(C)C)O
12	alpha-pinene	6654	CC1=CCC2CC1C2(C)C
13	beta-pinene	14896	CC1(C2CCC(=C)C1C2)C
14	Limonene	22311	CC1=CCC(CC1)C(=C)C
15	Seychellene	519743	CC1CCC2(C(=C)C3CCC2(C1C3)C)C
16	α-Humulene	6508206	CC1=CCC(C=CCC(=CCC1)C)(C)C
17	Germacrene D	6436582	CC1=CCCC(=C)C=CC(CC1)C(C)C
18	Aciphyllene	565709	CC1CCC(CC2=C(CCC12)C)C(=C)C
19	α-Bulnesene	6432384	CC1CCC2=C(CCC(CC12)C(=C)C)C
20	Norpatchoulenol	6451732	CC1(C2CCC3(C1(CC=CC3C2)O)C)C
21	Caryophyllene oxide	1742210	CC1(CC2C1CCC3(C(O3)CCC2=C)C)C
22	Pogostol	5320651	CC1CCC2C1CC(CCC2(C)O)C(=C)C

Table 2: Binding affinity between volatile compounds derived from *Pogostemon cablin* Benth. and SARS-CoV-2 glycoprotein

Compounds	Binding affinity (kcal/mol)
β-Guaiene	-7.4
α-Bulnesene	-7.2
(E)-β-Caryophyllene	-7.1
α-Guaiene	-7.0
Trans-Caryophyllene	-7.0
Sulabiroins A (reference control)	-6.8
α-Patchoulene	-6.8
gamma-elemene	-6.8
Pogostol	-6.8
Seychellene	-6.8
beta-Elemene	-6.7
Patchouli alcohol	-6.7
Germacrene D	-6.6
MLN-4760 (control)	-6.4
Aciphyllene	-6.4
Norpatchoulenol	-6.4
Caryophyllene oxide	-6.3
Beta-patchoulene	-6.2
αhumulene	-5.9
beta-Caryophyllene	-5.9
beta Pinen	-5.9
Alpha pinen	-5.8
Pogostone	-5.8
limonene	-5.5

Molecular docking analysis is conducted by using a calculation approach to measure the interaction between protein to small molecule. The analysis could be used to identify the inhibition ability of small molecules [14]. The utilization of the volatile compound of *Pogostemon cablin* Benth as an inhibitor candidate of SARS-CoV-2 glycoprotein showed that only five volatile compounds had lower binding affinity as compared to the control. Those selected volatile compounds, such as β-Guaiene, α-Bulnesene, E)-β-Caryophyllene, α-Guaiene, and Trans-Caryophyllene (table 2). However, all of those compounds were not specifically bind into RBD site of glycoprotein. The result depicted that there is only caryophyllene oxide which naturally bind into RBD site of glycoprotein together with the control MLN-4760 (fig. 1). While, sulabiroins A was bind to another part of glycoprotein. Furthermore, the complex of compound caryophyllene oxide-SARS-CoV-2 glycoprotein was taken for visualization and further analysis. The visualization of this complex was served the information of specific location of interaction [15]. It is essential to define the ability of small molecules to induce the function of protein.



Fig. 1: Visualization complex of SARS-CoV-2 glycoprotein (PDB: 6VXX) with several ligand: Sularboins A (wheat), MLN 4760 (magenta), and caryophyllene oxide (dark blue). Location of the receptor-binding domain (RBD) is indicated by yellow color dan the receptor-binding motif (RBM) is indicated by red color (coil)

Complex of caryophyllene oxide and SARS-CoV-2 glycoprotein was addressed for further analysis to identify the amino residue within that interaction. Result showed that both hydrogen bonds and hydrophobic bonds were formed within the interaction (fig. 2). In brief, caryophyllene oxide shared several bonds, which similar as compared to MLN-4760. In a hydrogen bond, caryophyllene oxide shared interaction to Thr430 with stronger interaction in 3.20 Å as compared to MLN-4760. Furthermore, within hydrophobic interaction, caryophyllene oxide had a similar interaction with control, such as Glu516, Phe429, and Asp428 (table 3). This similar shared amino acid residue is revealed that both compounds was reside in the same site within structure of glycoprotein. Moreover, the hydrophobic bonds help for stable interaction [16].



Fig. 2: Interaction of amino acid residue between (A) MLN-4760 (control), (B) Sulabiroins A (reference control), and (C) Caryophyllene oxide with the active site of SARS-CoV-2 glycoprotein

Table 3: Amino acid residues between selected compounds with SARS-CoV-2 glycoprotein

Compounds	Hydrogen bond	Hydrophobic bond
MLN-4760 (Control)	Ser514: 2.80; 2.79Å Phe515: 3.08; 2.86; 3.08 Å Thr430: 2.99; 2.83 Å	Glu516, Phe429, Leu518, Asp428, Leu517
Sulabiroins A (Reference control)	Ser530: 3.08 Å	Lys529, Asn331, Phe329, Ile332, Lys528, Thr333, Pro330, Val362, Pro527, Gly526
Caryophyllene Oxide	Thr430: 3.20 Å	Phe515, Ser514, Glu516, Tyr396, Phe464, Phe429, Asp428, Pro426

Further analysis showed that Sulabiroins A as reference control did not bind to specific site in RBD as, similar to MLN-4760 and caryophyllene oxide. Therefore, only MLN-4760 and caryphyllene oxide which addressed for further analysis, including the drug-likeness analysis and toxicity analysis. The drug-likeness analysis exhibited that based on Lipinski's rule of five, the caryophyllene oxide had fulfilled all five parameters, including hydrogen donor, hydrogen acceptor, molecular weight, molecular refractivity, and CLogP as compared to control (table 4). Based on the Lipinski's rule of five, the appropriate compound for the drug should fulfil all those parameters or four parameters [17], Result showed that caryophyllene oxide had small molecular weight about 220.35 g/mol which suggested the possibility for appropriate absorption. Recent research showed that as the weight increased so that the absorption would be decrease [18]. Therefore, lower molecular weight of the compound is preferable to be developed as potential drugs. While the optimum hydrogen donor and hydrogen acceptor also essential for passive diffusion through cell membranes, including absorption and distribution [19].

Table 4: Druglikeness of *Pogostemon cablin* Benth compound based on the lipinski rule of five

No	Compounds	PubChem ID	Lipinski's rule of five				
			Ha (≤10)	Hd (≤5)	MR	MW (g/mol)	CLogP
1	MLN-4760	448281	6	3	107.76	428.31	2.62
2	Caryophyllene oxide	1742210	1	0	68.27	220.35	3.68

Further identification was addressed for toxicity analysis in order to identify the safety level of compounds for clinical study. Result showed that the caryophyllene oxide had low toxicity which is indicated by the tolerance of high doses of compound in 5000 mg/kg (table 5). In brief, it belongs to the toxicity class 5 with means that the compound might be harmful if swallowed between 2000 mg/kg<LD50 ≤ 5000 mg/kg. Results also demonstrated that caryophyllene oxide is less toxic as compared to control. This is an interesting result for further analysis *in vivo*.

Table 5: Toxicity class of *Pogostemon cablin* benth compound

No	Compounds	PubChem ID	Toxicity analysis		
			LD50 (mg/kg)	Toxicity class	Accuracy (%)
1	MLN-4760	448281	3000	5	67.38
2	Caryophyllene oxide	1742210	5000	5	100

CONCLUSION

Simulation on silico analysis showed that most of the volatile compounds of *Pogostemon cablin* Benth had the potential ability to interact with SARS-CoV-2 glycoprotein. Among those compounds, caryophyllene oxide demonstrated the most potent inhibitor by specifically bind to the RBD site of glycoprotein as compared to the control. Furthermore, caryophyllene oxide also showed high druglikeness ability based on the Lipinski rule of five and low toxicity with 100% accuracy. Therefore, caryophyllene oxide derived from *Pogostemon cablin* Benth is considered as a potential candidate of an inhibitor agent for SARS-CoV-2 glycoprotein.

ACKNOWLEDGMENT

This research was funded by Ministry of Education, Research, and Technology through Excellence Fundamental Research Grant in the University program 2021 (013/SP-Lit/AMD/lPPM-01/Dikbudristek/Multi/FTB/VII/2021).

FUNDING

This work was supported by grants from Excellence Fundamental Research Grant in University, Ministry of Education-Research and Technology 2022 (Hibah Penelitian Dasar Unggulan Perguruan Tinggi Kemendikbud-Ristek 2022) with contract number 068/SP-Lit/LPPM-01/KemendikbudRistek/Multi/FTB/III/2022 (on behalf of Dr. Ir. Popy Hartatie Hardjo).

AUTHORS CONTRIBUTIONS

Authors acknoeledged University of Surabaya, and Ministry of Education, Research and Technology, Indonesia for supporting this reseach.

CONFLICTS OF INTERESTS

Declared none

REFERENCES

1. Rintelen K, Arida E, Hauser C. A review of biodiversity-related issues and challenges in megadiverse Indonesia and other Southeast Asian countries. RIO. 2017;3:e20860.
2. Ansori ANM, Kusala MKJ, Irawan H, Putri N, Fadholly A, Proboningrat A. Citrus reticulata extract as biocides to control Aedes aegypti, the vector of dengue. Biosci Res. 2018;15:1661-5.
3. Ansori ANM, Kharisma VD, Parikesit AA, Probojati RT, Rebezov M, Scherbakov P. Bioactive compounds from mangosteen (Garcinia mangostana L.) as an antiviral agent via dual inhibitor mechanism against SARS-CoV-2: an *in silico* approach. Pharmacogn J. 2022;14(1):85-90.
4. Hardjo PH, Susanto DPS, Savitrim WD, Purwanto MGM. Shoot multiplication of Pogostemon cab lin var Sidikalang and patchouli oil profile. Nus Biosci. 2019;11(2):123-7.
5. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020;27(3):325-8.
6. Mc Callum M, Waals AC, Bowen JE, Corti D, Vesler D. Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation. Nat Struct Mol Biol. 2020;27(10):942-9.
7. Jain NK, Agrawal A, Kulkarni GT, Tailang M. Molecular docking study on phytoconstituents of traditional ayurvedic srug tulsi (Ocimum sanctum Linn.) against COVID-19 Mpro enzyme: an *in silico* study. Int J Pharm Pharm Sci. 2022;14(4):44-50.
8. Dewi LK, Sahlan M, Paratami DK, A Agussalim, Sabir A. Identifying proporlis compounds potential to be COVID-19 therapies by targeting SARS-CoV-2 main protease. Int J Appl Pharm. 2021;13(2):103-10.
9. Mojumdar M, Kabir M, Hasan M, Ahmed T, Rahman MR, Akter Y. Molecular docking and pass prediction for the analgesic activity of some isolated compounds from Acalypha indica L. and ADME/T property analysis of the compounds. World J Pharml Res. 2016;5(7):1761-70.

10. Goel RK, Singh D, Lagunin A, Proikov VJMCR. PASS-assisted exploration of new therapeutic potential of natural products. Med Chem Res. 2011;2(9):1509-14.
11. Khurana N, Ishar MPS, Gajbhiye A, Goel RKJE. PASS-assisted prediction and pharmacological evaluation of novel nicotinic analogs for nootropic activity in mice. Eur J Pharmacol. 2011;662(1-3):22-30. doi: 10.1016/j.ejphar.2011.04.048, PMID 21554868.
12. Banerjee P, Eckert AO, Schrey AK, Preissner R. Protox-II: a web server for the prediction of toxicity of chemicals. Nucleic Acids Res. 2018;46(W1):W257-63. doi: 10.1093/nar/gky318, PMID 29718510.
13. Duan L, Zheng Q, Zhang H, Niu Y, Lou Y, Wang H. The SARS-CoV-2 spike glycoprotein biosynthesis, structure, function, and antigenicity: implications for the design of spike-based vaccine immunogens. Front Immunol. 2020;11:576622. doi: 10.3389/fimmu.2020.576622, PMID 33117378.
14. Satya MS, Suma BV, Aiswariya. Molecular docking and ADMET studies of ethanonne, 1-(2-hydroxy-5-methyl phenyl) for antimicrobial properties. Int J Pharm Pharm Sci. 2022;14(6):24-7.
15. Rifaldi F, Mumpuni E, Kumala S, Yantih N, Aulena DN, Nafisa S. Molecular docking of Cymbopogon nardus (L.) rendle compounds as a protease inhibitor of SARS-CoV-2. Int J Appl Pharm. 2022;14(3):112-5.
16. Jha V, Dhamapurkar V, Thakur K, Kaur N, Patel R, Devkar S. *In silico* prediction of potential inhibitors for the M2 protein of influenza a virus using molecular docking studies. Asian J Pharm Clin Res. 2022;15(8):100-8.
17. Aiswariya SBV, Satya MS. Molecular docking and ADMET studies of benzotriazole derivatives tethered with isoniazid for antifungal activity. Int J Curr Pharm Res. 2022;14(4):78-80.
18. Chae SY, Jang MK, Nah JW. Influence of molecular weight on oral absorption of water-soluble chitosans. J Control Release. 2005;102(2):383-94. doi: 10.1016/j.jconrel.2004.10.012, PMID 15653159.
19. Coimbra JTS, Feghali R, Ribeiro RP, Ramos MJ, Fernandes PA. The importance of intramolecular hydrogen bonds on the translocation of the small drug piracetam through a lipid bilayer. RSC Adv. 2020;11(2):899-908. doi: 10.1039/d0ra09995c, PMID 35423709.

ISSN 0975-7058

International Journal of Applied Pharmaceutics

http://innovareacademics.in

Editorial Board

Editor-in-Chief

Dr. Gaurav Kant Saraogi
Sri Aurobindo Institute of Pharmacy, Indore-Ujjain State Highway, Indore, Madhya Pradesh, India
Email: editor@ijaponline.org, gauravsaraogi13@gmail.com

Associate Editors

Dr. Genta Ida
Department of Drug Sciences, University of Pavia, Italy
Email:ida.genta@unipv.it

Assistant Editors

Dr. Awesh Kumar Yadav
National Institute of Pharmaceutical Education and Research Raebareli, Uttar Pradesh, India
Email: aweshyadav@gmail.com

Dr. Arvind Gulbake
National Institute of Pharmaceutical Education and Research: Changsari, Assam, India
Email: arvind.gulbake@gmail.com

Editorial Members

Dr. Kailash C. Petkar
Scientist 'C', Government of India, DSIR, Min. of Science and Technology, New Delhi, India

Email: petkar.kailash@gmail.com

Dr. Alankar Shrivastava
Amity Institute of Pharmacy, Amity University, Raipur, Chhattisgarh, India

Email: alankarshrivastava@gmail.com

Dr. Tarang Nema

International Flavours and Fragnances, Singapore

Dr. Carlotta Marianecci
Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Universita di Roma, Rome, Italy

Email: carlotta.marianecci@uniroma1.it

Dr. Manoj Nahar
Sun Pharmaceutical Industries Limited, Vadodara, Gujarat, India

Email: mnjnahar@yahoo.co.in

Dr. Tarek Abdelnapy Ahmed
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, KAU, Jeddah, KSA

Email: dr_tarek_nour@yahoo.com

Dr. Elizabeth Igne Ferreira
Faculty of Pharmaceutical Sciences, University of Sao Paulo, Brazil

Email: elizabeth.igne@gmail.com

Dr. Surya Prakasarao Kovvasu
Western University of Health Sciences, Pomona, California, USA

Email: skovvasu@westernu.edu

Dr. N. Kanagathara
Saveetha School of Engineering, Saveetha University, Chennai, India

Email: kanagathara23275@gmail.com

Dr. Mohammed Elmowafy Gomaa Aburaia
Department of Pharmaceutics, College of Pharmacy, Jouf University, Saudi Arabia

Email: melmowafy@ju.edu.sa

Dr. Liang Chen
Wenzhou Medical University, Wenzhou, P. R. China

Email: cheng_zhuan0101@wuxibiologics.com

Dr. Franca Castiglione
Department “G. Natta”, Politecnico di Milano, Italy

Email: franca.castiglione@polimi.it

Dr. Iman Emam Omar Gomaa
Faculty of Pharmacy, University for Modern Sciences and Arts (MSA)” Cairo - Egypt

Email: igomaa@msa.eun.eg

Dr. Basant Amarji
UIPS, Punjab University, Chandigarh, Punjab, India

Email: basantamarji@gmail.com

Dr. Rabab Kamel
Pharmaceutical Technology Department, National Research Centre, Egypt

Email: drrababk@hotmail.com

Dr. Satish Shilpi
Ravishankar College of Pharmacy, Bhopal, MP, India

Email: shilpisatish@gmail.com

Dr. Umeyor Chukwuebuka Emmanuel
Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria

Email: ec.umeyor@unizik.edu.ng

Dr. Yosra S.R. Elnaggar
Faculty of Pharmacy and Drug Manufacturing, Pharos University, Alexandria, Egypt

Email: yosra_pharm@yahoo.com

Dr. Sumeet Kapoor

IIT New Delhi, India

Email: s.kapooriitd@gmail.com

Dr. Arif Nur Muhammad Ansori

Faculty of Science and Technology, Universitas Airlangga, Surabaya, Indonesia

Email: ansori.anm@gmail.com

Dr. Dinesh Nyavanandi

Research Scientist, Formulation Development Cerevel Therapeutics, MA 02141, USA

Email: ndinesh624@gmail.com

Online ISSN: 0975–7058

INDEXED By Scopus

CONTINUED IN 2024 [Q2]

How we claim? Click Scopus indexing IJAP 2024 to learn and understand

1.4 2023 CiteScore

52nd percentile

Powered by Scopus

UGC Approved

ज्ञान-विज्ञान विमुक्तये

doi Crossref Content Registration

Plagiarism Check

International Journal of Applied Pharmaceutics
ISSN 0975-7058

Vol 15, Issue 1 (Jan-Feb), 2023

PUBLISHED: 07-01-2023

REVIEW ARTICLE(S)

LIPOSOMAL DRY POWDER INHALER: NOVEL PULMONARY TARGETED DRUG DELIVERY SYSTEM FOR THE TREATMENT OF LUNG CANCER

MANSING PATIL, PINKAL PATEL

1-12

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46611

NANO-DELIVERY SYSTEMS FOR ENHANCING ORAL BIOAVAILABILITY OF DRUGS

MENNA M. ABDELLATIF, SARA MOHAMED AHMED, MOHAMED A. EL-NABARAWI, MAHMOUD TEAIMA

13-19

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46758

4-CHLORO-7-NITROBENZOFURAZAN (NBD-CL) AS PRE AND POST-COLUMN DERIVATIZATION REAGENT FOR AMINE GROUPS ANALYSIS USING CHROMATOGRAPHY: A MINI-REVIEW

FEBRINA AMELIA SAPUTRI, RIMADANI PRATIWI

20-23

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46461

AN OVERVIEW: DEVELOPMENT OF COLON DRUG DELIVERY SYSTEM AND ITS APPLICATION AND LIMITATIONS

IYAN SOPYAN, ANITA DEWI PERMATASARI KOMARUDIN, JESSICA ANLIANI HUANG, INSAN SUNAN K. S.

24-30

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46681

A MINI REVIEW ON PROPERTIES, MECHANISM OF ACTION, PHARMACOKINETIC AND PHARMACODYNAMICS AND ANALYTICAL METHODS OF CARIPRAZINE

ALANKAR SHRIVASTAVA, RADHIKA AGGARWAL, RISHI PRATAP SINGH, RAKHI KHABIYA

31-35

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46651

FOCUS ON NIOSOMAL–BASED DRUG DELIVERY SYSTEMS FOR NASAL ROUTE: APPLICATIONS AND CHALLENGES

SAEED A. S. AL-ZUHAIRY, HOSSAM`` S. EL-SAWY, MOHAMED A. EL-NABARAWI, MAHMOUD H. TEAIMA

36-43

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46280

HIBISCUS ROSA-SINENSIS MUCILAGE AS A FUNCTIONAL POLYMER IN PHARMACEUTICAL APPLICATIONS: A REVIEW

NURUL AIMAN YAHAYA, NOR KHAIZAN ANUAR, NOR MAZIAH SAIDIN

44-49

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46159

NICLOSAMIDE: A POTENTIAL TREATMENT OPTION FOR COVID-19

SHWETA VIBHUTE, ADITI KASAR, HRISHIKESH MAHALE, MAHESH GAIKWAD, MADHUR KULKARNI

50-56

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.45850

MECHANISM OF ACTION, SYNTHESIS, PROPERTIES AND ANALYTICAL METHODS OF CABOZANTINIB

AKANKSHA DWIVEDI, RAKHI KHABIYA, ALANKAR SHRIVASTAVA, SIDDHARTH TYAGI, KANDASAMY NAGARAJAN, G. N. DARWHEKAR

57-65

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46409

ORIGINAL ARTICLE(S)

A PHYSIOCHEMICAL STUDY ON DRUG DELIVERY OF METFORMIN HCL-LOADED CS-PLGA NANOPARTICLES

YUTTANA SUDJAROEN, KANITTADA THONGKAO, PIMPORN THONGMUANG

66-71

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.45842

NOVEL QUERCETIN NANOEMULGEL OPTIMIZATION: GELLING AGENTS EVALUATION AND THE APPLICATION OF RESPONSE SURFACE METHODOLOGY

CHRISTOFORI MARIA RATNA RINI NASTITI, RINI DWIASTUTI, FLORENTINUS DIKA OCTA RISWANTO

72-78

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46585

ADVANCES IN AMELIORATING RHEUMATOID ARTHRITIS BY ANDROGRAPHOLIDE ETHOSOME-BASED GEL: PHARMACOKINETIC AND ACTIVITY STUDY IN RATS

KARTIKA FIDI ASTUTI, SILVIA SURINI, ANTON BAHTIAR

79-86

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46350

IMPORTANCE OF SUFFICIENT TIME POINTS FOR EFFICIENT PHARMACOKINETIC (PK) COMPARTMENTAL MODELING

TIRTHA NANDI

87-92

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46553

IDENTIFICATION OF POTENTIAL ACTIVITY OF VOLATILE COMPOUNDS DERIVED FROM POGOSTEMON CABLIN BENTH AS ANTIVIRAL OF SARS-COV-2

YULANDA ANTONIUS, JEREMI ONGKO, POPY HARTATIE HARDJO

93-97

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.43571

MODELING, BINDING SITE, AND IMMUNOGENICITY ANALYSIS OF GENES ENCODING L-ASPARAGINASE FROM ARTHROSPIRA PLATENSIS NIES 39

ASEP A. PRIHANTO, HAPPY NURSYAM, RAHMI NURDIANI, HIDAYATUN MUYASYAROH, ROYANI L. HAYATI, ANIS MIFTACURROCHMAH

98-103

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46177

OPTIMIZATION AND PHYSICAL CHARACTERIZATION OF QUERCETIN NANOEMULGEL FORMULA AS AN ANTIBACTERIAL AGENT

RINI DWIASTUTI, KATARINA NORALITA BAHAR GUMILAR, HARTATI YULIANI

104-110

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46737

IDENTIFICATION AND IN SILICO ANALYSIS OF INHIBITOR ON THE WNT/B-CATENIN SIGNALING PATHWAY AS POTENTIAL DRUG FOR COLON CANCER

SALBIAH RIDWAN, LINDA ERLINA, ANTON BAHTIAR, DEWI SUKMAWATI

111-120

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46570

ENHANCED AQUEOUS SOLUBILITY AND IN VITRO DISSOLUTION OF THE ANTI-HYPERLIPIDEMIC AGENT USING SYNTHESIZED SOLID DISPERSION CARRIER

DARSHAN R. TELANGE, SURENDRA S. AGRAWAL, ANIL M. PETHE, ANKITA V. HADKE

121-130

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46657

DESIGN AND OPTIMIZATION OF FLUCONAZOLE-LOADED PHARMACOSOME GEL FOR ENHANCING TRANSDERMAL PERMEATION AND TREATING FUNGAL INFECTIONS THROUGH BOX-BEHNKEN DESIGN

S. NAVEENTAJ, Y. INDIRA MUZIB, R. RADHA

131-140

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46413

IN SILICO EVALUATION OF BINDING INTERACTION AND ADME PROPERTIES OF NOVEL 5-(THIOPHEN-2-YL)-1,3,4-OXADIAZOLE-2-AMINE DERIVATIVES AS ANTI-PROLIFERATIVE

AGENTS

YOUSEF SABAH ALI, MONTHER FAISAL MAHDI, BASMA M. ABD RAZIK

141-146

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46488

THIOLATED MORINGA EXUDATE GUM AS IMPROVED BIO-MUCOADHESIVE AGENT IN THE FORMULATIONS OF DENTAL PASTE AND GEL

PRANAB KUMAR BANDYOPADHYAY, AMIT KUMAR NAYAK

147-155

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46647

INTRANASAL FORMULATION AND CHARACTERIZATION OF CHITOSAN MICROSPHERE FOR IMPROVING IN VITRO MUCOADHESION, RESIDENCE TIME AND ABSORPTION RATE OF PREGABALIN

ANIL PETHE, ANKIT HADKE, SURENDRA AGRAWAL, DARSHAN TELANGE

156-165

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46359

DEVELOPMENT AND CHARACTERIZATION OF PLANT OIL-BASED POTENT ANTICHOLINESTERASE MICROEMULSION CONTAINING WITHANIA SOMNIFERA EXTRACT WITH ENHANCED TRANSDERMAL DELIVERY OF PHYTOCONSTITUENTS FOR THE TREATMENT OF COGNITIVE DISORDERS

SNEH PRIYA, DIVYA JYOTHI, CYNTHIA LIZZIE LOBO

166-172

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46468

IMPROVING SOLUBILITY OF METHOTREXATE BY SOLID DISPERSION

MUQDAM MAHDI MOHAMAD ALI ALALI, JINAN M. AL-MOUSAWY, ZAHRAA MOHAMMED KADHIM, JAMAL ALI ASHOOR

173-177

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46490

FORMULATION AND IN VITRO CHARACTERISATION OF GLUCOSE-RESPONSIVE NANOCAPSULES FOR THE DELIVERY OF M-INSULIN

NIKHAR VISHWAKARMA, SURESH P. VYAS
178-185

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46511

INTERACTIONS OF XANTHONE COMPOUNDS FROM THE MANGOSTEEN (GARCINIA MANGOSTANA L) PERICARPS AGAINST INOS, COX-1, AND COX-2 ENZYME RECEPTORS AS ANTI-INFLAMMATORY

DWINTHA LESTARI, RISKA PERMATA SARI, IDA MUSFIROH, SANDRA MEGANTARA, MEILINDA SETYA PRACEKA, NUR KUSAIRA KHAIRUL IKRAM, MUCHTARIDI
186-194

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.45861

A MODEST UV SPECTROPHOTOMETRIC ASSISTED BY CHEMOMETRIC APPROACH FOR VERIFICATION OF ACETAMINOPHEN LEVEL IN VARIOUS MANUFACTURED TABLETS AND SYRUPS IN INDONESIAN PHARMACIES

MUHAMMAD ABDURRAHMAN MUNIR, AHLAM INAYATULLAH, SOFIAN IBRAHIM, IMRAM RADNE RIMBA PUTRI, EMELDA EMELDA, ANNISA FATMAWATI, NURHIDAYANTI NURHIDAYANTI
195-205

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46290

MOLECULAR DOCKING STUDY AND PHARMACOPHORE MODELLING OF URSOLIC ACID AS AN ANTIMALARIAL USING STRUCTURE-BASED DRUG DESIGN METHOD

FAIZAL HERMANTO, ANAS SUBARNAS, AFIFAH BAMBANG SUTJIATMO, AFIAT BERBUDI
206-211

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46298

THE EFFECT OF OLIVE OIL, TWEEN 60 AND SPAN 20 ON PHYSICAL CHARACTERISTICS OF QUERCETIN NANOEMULGEL

FETIANA CHRISMAURIN, RINI DWIASTUTI, LUTFI CHABIB, SRI HARTATI YULIANI
212-217

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46423

OPTIMIZATION, DEVELOPMENT AND EVALUATION OF REPAGLINIDE CONTROLLED RELEASE GASTRO-RETENTIVE FLOATING TABLET USING CENTRAL COMPOSITE DESIGN

MAHENDRA PATEL, MASHEER AHMED KHAN
218-226

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46493

OPTIMIZATION, FORMULATION AND CHARACTERIZATION OF NANO BASED TDDS OF EPLERENONE

SHINDE RAMESH VITHOBA, MALARKODI VELRAJ
227-233

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.45433

CENTRAL COMPOSITE FACE-CENTERED DESIGN-BASED OPTIMISATION, DEVELOPMENT AND CHARACTERISATION OF FAVIPIRAVIR-LOADED PLGA NANOPARTICLES

VENKATA KAVYA R, JEEVANA JYOTHI B.
234-249

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46289

MOLECULAR DYNAMICS SIMULATIONS OF THE STK630921 INTERACTIONS TO INTERLEUKIN-17A

FRANSISCUS DEDDY RIANDONO, ENADE PERDANA ISTYASTONO
250-255

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46369

BOX-BEHNKEN DESIGN FOR OPTIMIZATION OF FORMULATION VARIABLES FOR CONTROLLED RELEASE GASTRORETENTIVE TABLET OF VERAPAMIL HYDROCHLORIDE

INDURKHYA ARPNA, KHAN AHMED MASHEER
256-263

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46489

ANTICANCER ACTIVITY OF SILVER NANOPARTICLE OF PRODIGIOSIN ON LUNG CANCER

SHILPA KARNA, KAVITHA R., DAMODHARAN N.
264-268

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.43628

COMPARISON OF BIOPHARMACEUTICAL PARAMETERS OF CANNABINOIDS AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS BY QSAR METHOD

ANTON V. SYROESHKIN, DARIA A. GALKINA, DAIAANA D. OGOTOEVA, OLGA V. LEVITSKAYA, MARIYA A. MOROZOVA, TATIANA V. PLETENEVA

269-273

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.45990

PREDICTION OF ACTIVE COMPOUNDS OF MUNTINGIA CALABURA AS POTENTIAL TREAT-MENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASES BY NETWORK PHARMACOLOGY INTEGRATED WITH MOLECULAR DOCKING

NENDEN NURHASANAH, FADILAH FADILAH, ANTON BAHTIAR

274-279

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46281

DESIGN AND DEVELOPMENT OF PHYTOSOMAL SOFT NANOPARTICLES FOR LIVER TARGETING

MANJUSHA A. BHANGE, ANIL PETHE, ANKITA HADKE

280-289

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46303

THIOLATION OF FENUGREEK SEED POLYSACCHARIDE; UTILIZATION AS A NOVEL BIOMUCOADHESIVE AGENT IN DRUG DELIVERY

PRANAB KUMAR BANDYOPADHYAY, AMIT KUMAR NAYAK

290-297

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46459

PREPARATION AND EVALUATION OF ONCE-DAILY FLOATING GMO-ALGINATE MICROSPHERES CONTAINING FAMOTIDINE

AMIR IBRAHIM MOHAMED, MOHAMMED ISMAEL HERRY, MOHAMED A. KASSEM, AHMED EL-NABARAWI, MONA MOHAMED ABOELFOTOH EL KHATIB

298-307

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46503

ANTIPSORIATIC ACTIVITY OF HYDROGEL CONTAINING NANOSTRUCTURED LIPID CARRIER (NLC) ENTRAPPED WITH TRIAMCINOLONE ACETONIDE

ANILKUMAR J. SHINDE, SHREYASH D. TARLEKAR, RAVINDRA J. JARAG, FIROJ A. TAMBOLI

308-317

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46198

THE EFFECT OF CO-PROCESSED EXCIPIENTS DURING FORMULATION AND EVALUATION OF PEDIARIC LEVETIRACETAM ORODISPERSIBLE TABLETS IN RATS

MAHMOUD H. TEAIMA, HUSSIEN MOHAMED AHMED EL MESSIRY, TASNEEM DAHI OSMAN, MOHAMED A. EL-NABARAWI, DOAA A. HELAL

318-323

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.45298

DESIGN, DEVELOPMENT AND EVALUATION OF NOVEL MOUTH DISSOLVING FILM OF TOFACITINIB CITRATE

MEGHANA RAYKAR, MALARKODI VELRAJ

324-332

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46064

INVESTIGATION OF ANTI-SARS COV-2 ACTIVITY OF SOME TETRAHYDRO CURCUMIN DERIVATIVES: AN IN SILICO STUDY

AMRITA MURALIKRISHNAN, JASMIN KUBAVAT, MAHESH VASAVA, SRIKANTH JUPUDI, NAMITHA BIJU

333-339

VIEW ABSTRACT PDF DOWNLOAD PDF HTML

10.22159/ijap.2023v15i1.46288

CONFERENCE PROCEEDINGS

ABSTRACT BOOK

ABSTRACT BOOK

VIEW ABSTRACT PDF DOWNLOAD PDF

Online ISSN: 0975–7058

INDEXED By Scopus

CONTINUED IN 2024 [Q2]

How we claim? Click Scopus indexing IJAP 2024 to learn and understand

1.4 2023 CiteScore

52nd percentile

Powered by Scopus

UGC Approved

ज्ञान-विज्ञान विमुक्तये

doi Crossref Content Registration

Plagiarism Check

grammarly

Embase

It's Embase, Not Expanded Embase, Learn in 1 Min

MOST READ

FORMULATION AND EVALUATION OF TRANSDERMAL PATCHES OF PANTOPRAZOLE SODIUM
913

OCULAR DRUG DELIVERY SYSTEM: CHALLENGES AND APPROACHES
634

OVERVIEW ON FLOATING DRUG DELIVERY SYSTEM
600

DERMATOLOGIC GELS SPREADABILITY MEASURING METHODS COMPARATIVE STUDY
546

REGULATORY FRAMEWORK: VACCINE DEVELOPMENT IN US, INDIA AND EU
468

Our Journals || **Open Access Policy** || **Publication & Peer Review Policy** || **Publication Ethics**
The publication is licensed under a **Creative Commons License** (CC BY). **View Legal Code**
Copyright © 2024 All Rights Reserved, **Innovare Academic Sciences** | Powered By **CyberDairy**

International Journal of Applied Pharmaceutics

COUNTRY

India

Universities and research institutions in India

Media Ranking in India

SUBJECT AREA AND CATEGORY

Pharmacology, Toxicology and Pharmaceutics

Pharmaceutical Science

Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

PUBLISHER

Innovare Academics Sciences Pvt. Ltd

H-INDEX

25

PUBLICATION TYPE

Journals

ISSN

09757058

COVERAGE

2011-2023

SCOPE

Information not localized

Join the conversation about this journal

Quartiles

FIND SIMILAR JOURNALS options

1
Asian Journal of Pharmaceutical and Clinical
IND
56% similarity

2
International Journal of Drug Delivery Technology
IND
42% similarity

3
Asian Journal of Pharmaceutics
IND
40% similarity

4
Drug Delivery Letters
NLD
40% similarity

5
Drug Development and Industrial Pharmacy
USA
39% similarity

Premium Science online





















← Show this widget in your own website

Just copy the code below and paste within your html code:

<a href="https://www.scima

SCImago Graphica

Explore, visually communicate and make sense of data with our **new data visualization tool**.

Metrics based on Scopus® data as of March 2024

Okta 2 months ago

Dear Editor,
Is IJAP Q2 or Q3 in Pharmacology, Toxicology, and Pharmaceutics? in the list appear as Q3, but in the Scopus and the journal website it's categorized as Q2 since the last year (2023).

reply

SCImago Team

Melanie Ortiz 2 months ago

Dear Okta,
Thank you for contacting us.
As you probably already know, our data come from Scopus, they annually send us an update of the data. This update is sent to us around April / May every year.
The calculation of the indicators is performed with the copy of the Scopus database provided to us annually. Regarding your inquiry about the Quartile distribution process at SCImago, the journals are ranked and distributed in 4 equal groups based on their SJR value, unlike Scopus, who ranks the publications by percentiles based on the journal's CiteScore.
The Quartile methodology, like others that are used to group results f
can be applied to any indicator. Currently, Scopus offers information
ranking and the percentile they occupy according to the CiteScore indicator (https://service.elsevier.com/app/answers/detail/a_id/14880/supporthub/scopus/), which is perceived as an impact indicator, but that is different from the SJR, as the latter is also a normalized impact indicator (https://www.scimagojr.com/files/SJR2.pdf).
Both Scopus and SCImago Journal and Country Rank offer information on the SJR

Premium Science online

indicator for every journal, although the position of each of the publications and the quartile in which it is located according to the SJR can be consulted at https://www.scimagojr.com.
According to the above, the difference in the information consulted on the Scopus journal's profile and in Scimagojr.com lies in the fact that they represent the position of the journal based on two different indicators, which are not directly comparable because they measure two different dimensions: Impact (CiteScore) and Normalized Impact (SJR). Additionally, it is important to keep in mind that, although the quartiles in SJR tend to be distributed in 4 groups of equal size and that the journals appear sorted by the highest SJR to the lowest SJR, it is not always possible due to ties in SJR values and, therefore, journals with the same SJR must be distributed within the same quartile, which may lead to differences in the number of journals within that quartile.
Best Regards,
SCImago Team

A **Azad Sadraddin** 3 months ago

If the scientific journal has a Q2, how much does it compare to the IF?

reply

SCImago Team

Melanie Ortiz 3 months ago

Dear Azad, thank you very much for your comment. SCImago Journal and Country Rank uses Scopus data, our impact indicator is the SJR (Check it above). We suggest you consult the Journal Citation Report for other indicators (like Impact Factor) with a Web of Science data source. Best Regards, SCImago Team

M **Michelle** 1 year ago

Dear SCImago Team,

Is this journal still indexed as Q3 since the coverage is only until 2022 and it's already 2023.
Thankyou

reply

SCImago Team

Melanie Ortiz 1 year ago

Dear Michelle,
Thank you for contacting us. Our data come from Scopus, they annually send us an update of the data. This update is sent to us around April / May every year. The SJR for 2022 was released on 1st May 2023. Therefore, the indicators for 2023 will be available in May/June 2024.
Best Regards, SCImago Team

L **Lana** 2 years ago

Publisher this journal is difference with list from scimago. What is right?

reply

SCImago Team

Melanie Ortiz 2 years ago

Dear Lana,
Thank you for contacting us. Could you please expand a little bit on your comment?
Best Regards, SCImago Team

N **Neelam Pawar** 2 years ago

Hi

reply

SCImago Team

Melanie Ortiz 2 years ago

Dear Neelam, welcome and thanks for your participation! Best Regards, SCImago Team

Premium Science online

N **Nur Alam Abdullah** 3 years ago

Dear editorial team of the International Journal of Applied Pharmaceutics, I would like to ask how long it will take us as authors to get confirmation of the rejection or acceptance of our manuscript. tx regards.

reply

SCImago Team

Melanie Ortiz 3 years ago

Dear Nur,
Thank you for contacting us.
We are sorry to tell you that SCImago Journal & Country Rank is not a journal. SJR is a portal with scientometric indicators of journals indexed in Elsevier/Scopus.
We suggest you visit the journal's homepage or contact the journal's editorial staff , so they could inform you more deeply.
Best Regards, SCImago Team

S **sri laksemi** 3 years ago

Dear Schimago, Is International Journal of Applied Pharmaceutics still in schimago journal rank? usually there is homepage of the journal in the site of the journal in Schimago, but why there is no homepage or how to publish in this journal site in schimago?

reply

SCImago Team

Melanie Ortiz 3 years ago

Dear Sri,
Thank you for contacting us.
We inform you that all the information referring to the website of this Journal is not available in our website (you'll see "Information not localized") due to the fact that we could not verify that information with absolute reliability.
Best Regards,
SCImago TEAM
Dear Sir/Madam,
Thank you for contacting us.
We inform you that all the information referring to the website of this Journal is not available in our website (you'll see "Information not localized") due to the fact that we could not verify that information with absolute reliability.
Best Regards,
SCImago TEAM

B **Burhanuddin D Pasiga** 4 years ago

Dear

How much APC ?

reply

SCImago Team

Melanie Ortiz 4 years ago

Dear Burhanuddin,
thank you for contacting us.
Unfortunately, we cannot help you with your request, we suggest you visit the journal's homepage or contact the journal's editorial staff , so they could inform you more deeply.
Best Regards, SCImago Team

F **Faridah** 4 years ago

Dear sir

I would like to ask. Whether this journal accepts computational chemistry research and how much it costs for publication in this journal.

Thank you

Faridah

reply

Premium Science online

SCImago Team

Melanie Ortiz 4 years ago

Dear Faridah,
thank you for contacting us.
Unfortunately, we cannot help you with your request, we suggest you visit the journal's homepage or contact the journal's editorial staff , so they could inform you more deeply.
Best Regards, SCImago Team

J **Julaeha Julaeha** 5 years ago

Is this predatory journal? Or every journals in scimagojr database are guaranteed none predatory journal

reply

SCImago Team

Melanie Ortiz 5 years ago

Dear Julaeha, SJR is a portal with scientometric indicators of journals indexed in Scopus. All the data have been provided By Scopus /Elsevier and SCImago doesn´t have the authority over this data. For more information about predatory journals you can check the link below:
https://beallslist.weebly.com/.

Best regards, SCImago Team

BISWARANJAN PAITAL 6 years ago

Thanks Elena.

reply

Biswaranjan Paital 6 years ago

Hello there,
Is there any correlation exist between Scimago journal value with that of SCI impact factor provided by Claryvate Analytics.
Best
Dr. Paital

reply

SCImago Team

Elena Corera 6 years ago

Dear Biswaranjan, Ttey are two indicators that are calculated differently and with different databases and number of different indexed journals. There is a bibliography on the degree of correlation, which is high, but taking into account the three existing differences. Best Regards,
SCImago Team

D **Dr. Amer taqa** 6 years ago

Dear sir
Greetings
Have a nice day. Did your journal indexed in Scopus database and if it publish in medical field.
Waiting for your reply.
Best regards

reply

SCImago Team

Elena Corera 6 years ago

Dear Dr Amer, all the journals included in the SJR are indexed in Scopus. Elsevier / Scopus is our data provider. We suggest you look at the journal report to see which thematic fields are indexed. Best Regards, SCImago Team

Premium Science online

Leave a comment

Name

Email
(will not be published)

Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by: SCImago

Powered by: Scopus

Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2024. Data Source: Scopus®

EST MODUS IN REBUS
Horatio (Satire 1,1,106)

Legal Notice

Privacy Policy

Premium Science online

Source details

International Journal of Applied Pharmaceutics

Years currently covered by Scopus: from 2011 to 2024
Publisher: Innovare Academics Sciences Pvt. Ltd
ISSN: 0975-7058
Subject area: Pharmacology, Toxicology and Pharmaceutics: Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Source type: Journal

CiteScore 2023
1.4

SJR 2023
0.192

SNIP 2023
0.352

View all documents > | Set document alert | Save to source list

CiteScore | CiteScore rank & trend | Scopus content coverage

CiteScore 2023

$$1.4 = \frac{1{,}706 \text{ Citations } 2020 - 2023}{1{,}196 \text{ Documents } 2020 - 2023}$$

Calculated on 05 May, 2024

CiteScoreTracker 2024

$$1.4 = \frac{1{,}463 \text{ Citations to date}}{1{,}075 \text{ Documents to date}}$$

Last updated on 08 July, 2024 • Updated monthly

CiteScore rank 2023

Category	Rank	Percentile
Pharmacology, Toxicology and Pharmaceutics Pharmacology, Toxicology and Pharmaceutics (miscellaneous)	#21/43	52nd

View CiteScore methodology > | CiteScore FAQ > | Add CiteScore to your site

About Scopus

What is Scopus

Content coverage

Scopus blog

Scopus API

Privacy matters

Language

日本語版を表示する

查看简体中文版本

查看繁體中文版本

Просмотр версии на русском языке

Customer Service

Help

Tutorials

Contact us

ELSEVIER

Terms and conditions Privacy policy

All content on this site: Copyright © 2024 Elsevier B.V., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the Creative Commons licensing terms apply.
We use cookies to help provide and enhance our service and tailor content.By continuing, you agree to the use of cookies.

RELX™